EXECUTIVE ENGAGEMENTS
POOL
2273
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
409
Interactions with Platform & by Email
PARTICIPANTS
68
Unique # Participated
VALIDATIONS
22
Responses Validated*
COMPANIES
23
Responses Validated*
* Login for a full stack data experience
DATE
JAN 2022
TABLES
202
PAGES
264
EDITION
18
PRICE
USD 5450
CODE
MCP-1722
*Engagement stats are ongoing and dynamic
RESEARCH MODULES
EXECUTIVES
HIGHLIGHTS & REPORT INDEX
What's New for 2022?
» Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass Research Platform
» Complimentary updates for one year
Amid the COVID-19 crisis, the global market for Anti-Obesity Drugs estimated at US$2 Billion in the year 2020, is projected to reach a revised size of US$3.7 Billion by 2027, growing at aCAGR of 8.7% over the period 2020-2027. Prescription Drugs, one of the segments analyzed in the report, is projected to record 8.5% CAGR and reach US$3.3 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the OTC Drugs segment is readjusted to a revised 10.9% CAGR for the next 7-year period.
The Anti-Obesity Drugs market in the U.S. is estimated at US$606.3 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$638.2 Million by the year 2027 trailing a CAGR of 8.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8% and 7.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.1% CAGR.
SELECT PLAYERS
Eisai Co. Ltd. (Japan); F. Hoffmann-La Roche Ltd. (Switzerland); GlaxoSmithKline Plc; Novo Nordisk A/S (Denmark); Rhythm Pharmaceuticals (US); VIVUS Inc. (US)
SEGMENTS
» Type (Prescription Drugs, OTC Drugs)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Impact of Covid-19 and a Looming Global Recession |
| Obesity and Overweight Statistics |
| Recent Market Activity |
| Obesity - A Prelude |
| Anti-Obesity Drugs: A Market Characterized by High Unmet Needs |
| Currently Available Anti-Obesity Medications |
| Select Currently Available Short-term and Long-term Anti-Obesity Medication |
| Select Off-Label Drugs for Obesity |
| Saxenda Commands the AOM Market, Newer Drugs to Provide Impetus to Market Growth |
| Semaglutide: Highest Potential in the AOM Pipeline |
| Setbacks of Past Drugs |
| Positive Road Ahead for Belviq |
| Relaunch of Xenical |
| Relaunch of Contrave® |
| Reluctance among Patients, Physicians, and Payers Hurts Market Prospects |
| New Drug Development - High on the Agenda, Despite the Market Restraints |
| Anti-Obesity Drugs in Phase-III Clinical Trials: As of July 2018 |
| Anti-Obesity Drugs in Phase-II Clinical Trials: As of July 2018 |
| Anti-Obesity Drugs in Phase-I Clinical Trials: As of July 2018 |
| Diabetes Drug Companies Attempt to Foray into the Anti-Obesity Drugs Space |
| Competitive Landscape |
| Novo Nordisk - The Leading Player in the Market |
| The United States - The Largest Obesity and Anti-Obesity Market |
| Europe - A Market with Vast Potential |
| Obesity Creeps Up in Developing Countries |
| Anti-Obesity Drugs – Global Key Competitors Percentage Market Share in 2022 (E) |
| Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) |
| 2. FOCUS ON SELECT PLAYERS |
| F. Hoffmann-La Roche Ltd. (Switzerland) |
| GlaxoSmithKline Plc. (UK) |
| Eisai Co., Ltd. (Japan) |
| Novo Nordisk A/S (Denmark) |
| Rhythm Pharmaceuticals (USA) |
| VIVUS, Inc. (USA) |
| 3. MARKET TRENDS & DRIVERS |
| Alarming Rise in Global Obesity Levels - The Major Growth Factor |
| Classification of BMI |
| Rising Incidence of Chronic Diseases Associated with Obesity Drive the Market Expansion |
| Growing Middle Class Population to Drive the Market Growth |
| Childhood Obesity - A Market with Unmet Needs |
| Commercial Weight-Loss Companies Foray into the Market |
| Online Drug Stores Boost Sales |
| Barriers to Development of Effective Drugs |
| Regulatory Additions - A Barrier to Entry? |
| High Drug Development Costs - A Major Setback |
| Weight Loss Alternatives - A Market Dampener |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Anti-Obesity Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Prescription Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Prescription Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027 |
| World Recent Past, Current & Future Analysis for OTC Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for OTC Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027 |
| World Anti-Obesity Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2012 through 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E) |
| USA Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| USA 7-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2021 & 2027 |
| CANADA |
| Canada Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Canada 7-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2021 & 2027 |
| JAPAN |
| Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E) |
| Japan Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Japan 7-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2021 & 2027 |
| CHINA |
| Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E) |
| China Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| China 7-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2021 & 2027 |
| EUROPE |
| Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E) |
| Europe Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| Europe 7-Year Perspective for Anti-Obesity Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2021 & 2027 |
| Europe Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Europe 7-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2021 & 2027 |
| FRANCE |
| Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E) |
| France Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| France 7-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2021 & 2027 |
| GERMANY |
| Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E) |
| Germany Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Germany 7-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2021 & 2027 |
| ITALY |
| Italy Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Italy 7-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2021 & 2027 |
| UNITED KINGDOM |
| Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E) |
| UK Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| UK 7-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2021 & 2027 |
| REST OF EUROPE |
| Rest of Europe Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of Europe 7-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2021 & 2027 |
| ASIA-PACIFIC |
| Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E) |
| Asia-Pacific Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific 7-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2021 & 2027 |
| REST OF WORLD |
| Rest of World Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of World 7-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2021 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 23 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com